Documenti fondamentali

Visualizza tutta la documentazione

Vai a

1481204

USP

Oxaliplatin

Name: Oxaliplatin
Brand: USP
Price: 2110 CHF

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione

Taglio della confezione	SKU	Disponibilità	Prezzo
125 mg		Per conoscere la disponibilità, visualizza il carrello	CHF 2’110.00

Informazioni su questo articolo

Formula empirica (notazione di Hill):

C₈H₁₄N₂O₄Pt

Numero CAS:

61825-94-3

Peso molecolare:

397.29

NACRES:

NA.24

PubChem Substance ID:

329750629

UNSPSC Code:

41116107

MDL number:

MFCD00866327

CHF 2’110.00

Per conoscere la disponibilità, visualizza il carrello

Richiedi un ordine in blocco

Servizio Tecnico

Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.

Permettici di aiutarti

Proprietà

grade

pharmaceutical primary standard

agency

USP

API family

oxaliplatin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

InChI key

ZROHGHOFXNOHSO-BNTLRKBRSA-L

Descrizione

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxaliplatin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Oxaliplatin Injection
Oxaliplatin for Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo	Y0000271	O9512	PHR1528
USP 1481204 Oxaliplatin	Y0000271 Oxaliplatin	Sigma-Aldrich O9512 Oxaliplatin	Supelco PHR1528 Oxaliplatin
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade -	grade certified reference material, pharmaceutical secondary standard
manufacturer/tradename USP	manufacturer/tradename EDQM	manufacturer/tradename -	manufacturer/tradename -
format neat	format neat	format -	format neat
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) -	application(s) pharmaceutical (small molecule)
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-30°C
API family oxaliplatin	API family oxaliplatin	API family -	API family oxaliplatin

Still not finding the right product?

Explore all of our products under Oxaliplatin

pictograms

GHS08,GHS05

signalword

Danger

hcodes

H317,H318,H334,H341,H351,H360FD,H362,H372

pcodes

P260 - P263 - P280 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.

L B J van Iersel et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40(11), 1557-1563 (2014-08-16)

To improve isolated hepatic perfusion (IHP), we performed a phase I dose-escalation study to determine the optimal oxaliplatin dose in combination with a fixed melphalan dose. Between June 2007 and July 2008, 11 patients, comprising of 8 colorectal cancer and

Platinum-RNA modifications following drug treatment in S. cerevisiae identified by click chemistry and enzymatic mapping.

Maire F Osborn et al.

ACS chemical biology, 9(10), 2404-2411 (2014-07-24)

With the importance of RNA-based regulatory pathways, the potential for targeting noncoding and coding RNAs by small molecule therapeutics is of great interest. Platinum(II) complexes including cisplatin (cis-diamminedichloroplatinum(II)) are widely prescribed anticancer compounds that form stable adducts on nucleic acids.

Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin.

Jennifer R Deuis et al.

Neuro-oncology, 16(10), 1324-1332 (2014-04-10)

Peripheral neuropathy is the major dose-limiting side effect of cisplatin and oxaliplatin, and there are currently no effective treatments available. The aim of this study was to assess the pharmacological mechanisms underlying chemotherapy-induced neuropathy in novel animal models based on

Visualizza tutti i documenti correlati

Numero articolo commerciale globale

SKU	GTIN
1481204-125MG	04061838737861

Questions

Reviews

No rating value